JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis


BACKGROUND
The V617F mutation, which causes the substitution of phenylalanine for valine at position 617 of the Janus kinase (JAK) 2 gene (JAK2), is often present in patients with polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis. However, the molecular basis of these myeloproliferative disorders in patients without the V617F mutation is unclear.

METHODS
We searched for new mutations in members of the JAK and signal transducer and activator of transcription (STAT) gene families in patients with V617F-negative polycythemia vera or idiopathic erythrocytosis. The mutations were characterized biochemically and in a murine model of bone marrow transplantation.

RESULTS
We identified four somatic gain-of-function mutations affecting JAK2 exon 12 in 10 V617F-negative patients. Those with a JAK2 exon 12 mutation presented with an isolated erythrocytosis and distinctive bone marrow morphology, and several also had reduced serum erythropoietin levels. Erythroid colonies could be grown from their blood samples in the absence of exogenous erythropoietin. All such erythroid colonies were heterozygous for the mutation, whereas colonies homozygous for the mutation occur in most patients with V617F-positive polycythemia vera. BaF3 cells expressing the murine erythropoietin receptor and also carrying exon 12 mutations could proliferate without added interleukin-3. They also exhibited increased phosphorylation of JAK2 and extracellular regulated kinase 1 and 2, as compared with cells transduced by wild-type JAK2 or V617F JAK2. Three of the exon 12 mutations included a substitution of leucine for lysine at position 539 of JAK2. This mutation resulted in a myeloproliferative phenotype, including erythrocytosis, in a murine model of retroviral bone marrow transplantation.

CONCLUSIONS
JAK2 exon 12 mutations define a distinctive myeloproliferative syndrome that affects patients who currently receive a diagnosis of polycythemia vera or idiopathic erythrocytosis.
The myeloproliferative disorders comprise a spectrum of chronic hematologic diseases that are likely to arise from a mutant multipotent hematopoietic stem cell. The V617F somatic mutation in the Janus kinase (JAK) 2 gene (JAK2), which causes the substitution of phenylalanine for valine at position 617, has recently been found in the majority of patients with polycythemia vera and in many with essential thrombocythemia or idiopathic myelofibrosis. This gene encodes a cytoplasmic tyrosine kinase. The mutation, which occurs in the JAK homology 2 (JH2) negative regulatory domain, increases JAK2 kinase activity and causes cytokine-independent growth of cell lines and cultured bone marrow cells. Mutant JAK2 transfected into murine bone marrow cells produces erythroid differentiation and subsequent myelofibrosis in recipient animals, suggesting a causal role for the mutation.

Allele-specific polymerase chain reaction (PCR) can be used to detect the V617F mutation in approximately 95% of patients with polycythemia vera and in 50 to 60% of patients with essential thrombocythemia or idiopathic myelofibrosis. The mutation is also present in hematopoietic progenitors committed to granulocytic or erythroid differentiation and in purified hematopoietic stem cells from patients with polycythemia vera. Many patients with polycythemia vera or idiopathic myelofibrosis are homozygous for the V617F mutation, as a result of mitotic recombination affecting chromosome 9p, but homozygosity is rare in patients with essential thrombocythemia. The mutation occurs infrequently in patients with myelodysplasia or acute myeloid leukemia but does not occur in those with lymphoid tumors, epithelial cancers, or sarcomas.

The JAK2 mutation allows for a distinction between two subtypes of idiopathic myelofibrosis and essential thrombocythemia. The phenotype of V617F-positive, but not V617F-negative, essential thrombocythemia resembles that of polycythemia vera. However, patients with V617F-negative essential thrombocythemia do have cytogenetic abnormalities, dysplastic megakaryocytes, and a risk of transformation to myelofibrosis or acute myeloid leukemia, all of which are features of a myeloproliferative disorder. Activating mutations in the thrombopoietin receptor have been reported in 10% of patients with V617F-negative idiopathic myelofibrosis and in a few patients with essential thrombocythemia. However, the molecular basis of V617F-negative polycythemia vera is unknown.

Methods

Patients

We recruited patients from Addenbrooke’s Hospital in Cambridge, St. Thomas’ Hospital in London, and Belfast City Hospital in Belfast (all in the United Kingdom) and from those enrolled in the Myeloproliferative Disorders Study of Harvard University in Boston. Diagnoses assigned by local physicians were reviewed centrally and revised according to established criteria for polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis. The Addenbrooke’s National Health Service Trust Research Ethics Committee approved this study. Written informed consent was obtained from each patient.

Mutation screening

The isolation of granulocytes and T lymphocytes and hematopoietic colony assays were performed as previously described. Individual burst-forming units and erythropoietin-independent erythroid colonies were harvested into water and boiled. Primers for the coding exons of JAK1, JAK2, JAK3, the tyrosine kinase 2 gene (TYK2), and of two signal transducer and activator of transcription genes (STAT5A and STAT5B) are listed at www.sanger.ac.uk/genetics/CGP; all additional primers used are listed in Table 1 in the Supplementary Appendix (available with the full text of this article at www.nejm.org). We performed allele-specific PCR using DNA from granulocytes or from total peripheral blood, an annealing temperature of 62°C, JAK2 exon 12 control primers, and primers specific for the alleles containing the K539L mutation (leading to the replacement of lysine at position 539 with a leucine), the N542-E543del mutation (causing the deletion of asparagine at position 542 and glutamic acid at position 543), the F537-K539delinsL mutation (leading to the replacement of phenylalanine at position 537 through lysine at position 539 by a single leucine), or the H538QK539L mutation (causing a substitution of glutamine for histidine at position 538 and leucine for lysine at position 539). We amplified DNA from in vitro colonies using exon 12 primers and sequenced or genotyped the PCR products using digestion with AspI.
**BONE MARROW BIOPSY**

Bone marrow biopsy specimens from the iliac crest were fixed in neutral buffered formalin. Some were processed in paraffin and others in methylmethacrylate after decalcification in 5.5% EDTA. Sections (1 to 3 μm thick) were cut and visualized using hematoxylin and eosin or Wright–Giemsa stain. All stained sections were viewed under a light microscope (Olympus BX51) equipped with a 10×-H26.5 ocular lens. Low-power (20×) and high-power (40×) images were obtained with a digital camera (Pixera Pro150ES) and Studio 3.0.1 software (Adobe Systems).

**SITE-DIRECTED MUTAGENESIS AND PRODUCTION OF RETROVIRUS**

We introduced the mutations V617F, H538QK539L, K539L, N542-E543del, and F537-K539delinsL into murine Jak2 complementary DNA in a bicistronic retroviral vector encoding green fluorescent protein (MSCViresGFP), using QuikChange site-directed mutagenesis (Stratagene). The complete nucleotide sequence of each retroviral vector was confirmed before use. For the production of each retrovirus, equal amounts of Jak2 retroviral vector and packaging plasmids (Ecopak) were combined, incubated with FuGene (Roche) for 15 minutes, and then added to the human embryonic kidney-cell line, 293T. The supernatants were harvested 48 hours later and were used to transduce BaF3 cells expressing the murine erythropoietin receptor (BaF3/EpoR cells) or murine bone marrow cells.

**BAF3-CELL PROLIFERATION ASSAYS AND WESTERN BLOTTING**

BaF3/EpoR cells were maintained in RPMI-1640 medium containing 10% fetal-calf serum and 10% medium conditioned with WEHI-3B cells, as a source of interleukin-3, and infected with retroviral supernatants containing MSCViresGFP vectors encoding mutant or wild-type Jak2. The green fluorescent protein–positive population from each transduction was purified by flow-cytometric sorting 2 days later and was then expanded in RPMI-1640 medium with 10% fetal-calf serum and 10% WEHI-3B–conditioned medium for 3 to 8 days. To assay for growth-factor hypersensitivity, transduced BaF3/EpoR cells were cultured in the absence of interleukin-3, and the number of viable cells was measured at days 2 and 4 with the use of trypan-blue exclusion. Data from four independent experiments were combined in analyses.

For immunoprecipitation and Western blot studies, BaF3/EpoR cells expressing wild-type or mutant Jak2 were starved for 4 to 5 hours in RPMI-1640 medium containing 1% bovine serum albumin and were then pelleted and frozen for subsequent analysis. Cells stimulated with 10 U per milliliter of erythropoietin for 10 minutes served as a positive control. For the analysis of Jak2 and Stat5, 3×10⁷ cells were lysed in 10 mM TRIS–hydrochloric acid (pH 7.4) with 150 mM sodium chloride and 0.5% NP-40 buffer containing phosphatase and protease inhibitors. The protein supernatant was precipitated with anti-Jak2 antibody (Upstate Cell Signaling Solutions) or anti-Stat5 antibody (Santa Cruz Biotechnology). Precipitates were blotted with antibodies against phosphorylated Stat5 (phosphotyrosine at position 694) (Cell Signaling Technology), phosphorysine (4G10) (Upstate Cell Signaling Solutions), Jak2, or Stat5 (Santa Cruz Biotechnology). Alternatively, total cell lysates were resuspended in lithium dodecyl sulfate sample buffer (Invitrogen) and then blotted with antibodies against phosphorylated extracellular regulated kinase 1 and 2 (Erk1 and Erk2) (phosphothreonine at position 202 and phosphotyrosine at position 204 in Erk) or against total Erk (Cell Signaling Technology).

**BONE MARROW TRANSPLANTATION ASSAY IN MICE**

Bone marrow transplantation was performed as previously described. Briefly, retroviral supernatants were titrated by determining the percentage of BaF3 cells that were positive for green fluorescent protein 48 hours after the introduction of the retroviral vector. Supernatants containing equal titers of wild-type Jak2 or V617F or K539L Jak2 were used to transfect bone marrow cells. BALB/c donor mice were treated with 150 mg of 5-fluorouracil per kilogram of body weight, and cells harvested from femurs and tibias 7 days later were cultured for 24 hours in transplantation medium (RPMI-1640 medium, 10% fetal-calf serum, 6 ng of murine interleukin-3 per milliliter, 10 ng of human interleukin-6 per milliliter, and 10 ng of murine stem-cell factor per milliliter). Bone marrow cells were centrifuged at 2500 rpm for 90 minutes in the presence of 1 ml of retroviral supernatant and 10 μg of polybrene per 4×10⁶ cells. Exposure to retroviral supernatant and centrifugation
were repeated 1 day later. Aliquots of 1×10^6 bone
marrow cells were resuspended in 0.7 ml of Hank’s
balanced salt solution and then injected into lethal-
ly irradiated BALB/c mice. Peripheral-blood counts
and cell morphology were evaluated for each re-
cipient 38 days after transplantation.

**STATISTICAL ANALYSIS**
We used an unpaired Student’s t-test to compare
demographic and laboratory features at the time
of diagnosis between patients with a V617F JAK2
mutation and those with a JAK2 exon 12 mutation
and to compare peripheral-blood counts among

---

**Figure 1. Somatic Mutations of JAK2 Exon 12 in Patients with Polycythemia Vera or Idiopathic Erythrocytosis.**
Panel A shows DNA-sequence traces from peripheral-blood granulocytes and T lymphocytes and from erythropoie-
tin-independent erythroid colonies. Nucleotides are indicated by capital letters, with N representing sites at which
wild-type and mutant nucleotides are apparent at the same position. The traces reveal four acquired mutations within
JAK2 exon 12 (indicated by arrowheads), often with low-level involvement in granulocytes. Panel B (top) shows the
alignment of wild-type and mutant exon 12 JAK2 alleles (shown in red) (nucleotides are indicated by capital letters
and amino acids by bold capital letters; dashes indicate the positions of deleted nucleotides). The amino acid alignment
across multiple species (Panel B, bottom) shows conservation of the mutated amino acids, indicated in red.
SOMATIC MUTATIONS AFFECTING JAK2 EXON 12

Of the 73 patients with polycythemia vera in our original cohort, 2 did not have the V617F mutation4 and were studied further. In these two patients, mutations were not found in the coding exons of JAK1, JAK3, TYK2, STAT5A, or STAT5B. However, both patients had alterations in JAK2 exon 12 that affected residues lying approximately 80 amino acids before V617. One patient had a 6-bp in-frame deletion affecting positions 1611 to 1616, resulting in an F537-K539delinsL mutation. The second patient had a CAA→ATT mutation at positions 1614 through 1616, resulting in an H538QK539L mutation (Fig. 1A). These mutations were acquired, since they could be detected in peripheral-blood granulocytes but not in T lymphocytes.

JAK2 exon 12 mutations were identified in eight of an additional nine patients who received a diagnosis of V617F-negative polycythemia vera from their local physicians. The mutations were frequently present at low levels in granulocyte DNA but were readily identifiable in clonally derived erythropoietin-independent erythroid colonies (Fig. 1A). In total, four exon 12 alleles were identified, all of which had changes affecting conserved residues between K537 and E543 (Fig. 1); three of the alleles (in Patients 1 through 6) contained a K539L substitution (Fig. 1B). In total, four exon 12 alleles were identified, all of which had changes affecting conserved residues between K537 and E543 (Fig. 1); three of the alleles (in Patients 1 through 6) contained a K539L substitution (Fig. 1B). These mutations were not detected by sequencing granulocyte DNA from 55 patients with V617F-positive polycythemia vera, 25 patients with V617F-negative essential thrombocythemia, and 12 patients with V617F-negative cases of idiopathic myelofibrosis4 (and data not shown). Since mutation-bearing granulocytes may represent only a minority of peripheral blood granulocytes,4,10,29 DNA from an additional 90 patients with V617-negative essential thrombocythemia was screened using sensitive allele-specific PCR assays for each exon 12 mutation, but no mutations were detected (data not shown). These results indicate that JAK2 exon 12 mutations occur only in patients with a myeloproliferative disorder.

Table 1. Clinical Features of Patients with JAK2 Exon 12 Mutations at Diagnosis.*

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Age (yr)</th>
<th>JAK2 Mutation</th>
<th>Hemoglobin (g/dL)</th>
<th>White-Cell Count (×10^9/mm^3)</th>
<th>Platelet Count (×10^9/mm^3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>55</td>
<td>F537K539delinsL</td>
<td>13.4</td>
<td>17.9</td>
<td>14.4</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>59</td>
<td>F537K539delinsL</td>
<td>16.4</td>
<td>13.9</td>
<td>20.7</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>59</td>
<td>F537K539delinsL</td>
<td>30.8</td>
<td>20.5</td>
<td>28.8</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>27</td>
<td>H538QK539L</td>
<td>21.1</td>
<td>11.1</td>
<td>28.6</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>62</td>
<td>K539L</td>
<td>18.1</td>
<td>7.5</td>
<td>30.1</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>54</td>
<td>K539L</td>
<td>20.7</td>
<td>8.6</td>
<td>13.2</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>57</td>
<td>N542E543del</td>
<td>12.0</td>
<td>5.8</td>
<td>28.3</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>23</td>
<td>N542E543del</td>
<td>1.98</td>
<td>3.8</td>
<td>28.5</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>57</td>
<td>N542E543del</td>
<td>1.99</td>
<td>4.4</td>
<td>20.4</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>33</td>
<td>N542E543del</td>
<td>12.1</td>
<td>4.25</td>
<td>ND</td>
</tr>
</tbody>
</table>

* The normal range of serum erythropoietin before therapy is 5 to 25 IU per liter. The diagnosis was determined on the basis of criteria of the Polycythemia Vera Study Group. The presence or absence of erythroid colonies independent of erythropoietin were assessed in 2005 or 2006. The deletion in chromosome 20q was confirmed by microsatellite polymorphisms, and ND not determined.

† Neutrophil counts were 8,960 per cubic millimeter for Patient 2 and before therapy in all other patients.

‡ The serum erythropoietin level was measured after venesection therapy in Patient 2 and before therapy in all other patients.

The normal range of serum erythropoietin before therapy is 5 to 25 IU per liter. The diagnosis was determined on the basis of criteria of the Polycythemia Vera Study Group. The presence or absence of erythroid colonies independent of erythropoietin were assessed in 2005 or 2006. The deletion in chromosome 20q was confirmed by microsatellite polymorphisms, and ND not determined.

† Neutrophil counts were 8,960 per cubic millimeter for Patient 2 and before therapy in all other patients.

‡ The serum erythropoietin level was measured after venesection therapy in Patient 2 and before therapy in all other patients.

The New England Journal of Medicine

Downloaded from nejm.org at UQ Library on March 26, 2017. For personal use only. No other uses without permission.

Copyright © 2007 Massachusetts Medical Society. All rights reserved.
proliferative syndrome who present with erythrocytosis.

**CLINICAL PHENOTYPE ASSOCIATED WITH JAK2 EXON 12 MUTATIONS**

Table 1 shows the clinical and laboratory features of the patients with exon 12 mutations. All had platelet counts of 450×10^3 or less per cubic millimeter and neutrophil counts that were within the normal range or were insufficiently raised to fulfill the criteria for a diagnosis of polycythemia vera. A low serum erythropoietin level was found in four of eight tested patients, and in six of six tested patients, erythropoietin-independent erythroid colonies could be grown from peripheral-blood cells, a key feature of the myeloproliferative disorders. Central review of clinical and laboratory features revealed that six patients fulfilled the criteria of the Polycythemia Vera Study Group for polycythemia vera, and four patients fulfilled criteria for idiopathic erythrocytosis. Patients with exon 12 mutations were significantly younger at diagnosis than 86 patients from Addenbrooke’s Hospital who had V617F-positive polycythemia vera (median age, 52 years vs. 58 years; P = 0.003) and had significantly higher hemoglobin levels (mean, 202 g per liter vs. 180 g per liter; P = 0.002), lower white-cell counts (mean, 8.4×10^3 per cubic millimeter vs. 14.1×10^3 per cubic millimeter; P = 0.008), and lower platelet counts (mean, 311×10^3 per cubic millimeter vs. 605×10^3 per cubic millimeter; P < 0.001) (Table 2 in the Supplementary Appendix). Bone marrow trephine biopsy was performed in five patients at diagnosis; the biopsy specimens were examined in a blinded manner. All showed a characteristic pattern of erythroid hyperplasia without morphologic abnormalities of the megakaryocyte or granulocyte lineages (Fig. 2, and Fig. 1A in the Supplementary Appendix).

Hematopoietic progenitors that are homozygous for the V617F mutation are detectable in most patients with polycythemia vera. To seek such homozygosity in patients with exon 12 mutations, individual hematopoietic progenitors from Patients 3, 4, 5, and 7 were genotyped with the use of Asel digestion (Fig. 2B in the Supplementary Appendix), sequence analysis, or both. Homozygosity was not observed in any of the 151 erythroid colonies carrying an exon 12 mutation, whether they were grown in the presence or absence of erythropoietin (Fig. 2C in the Supplementary Appendix). In one patient, granulocyte–macrophage colonies were also heterozygous for the exon 12 mutation, demonstrating that this genetic change occurred at the level of the common myeloid progenitor or the hematopoietic stem cell.

**PROLIFERATION AND SIGNALING IN CELLS BEARING EXON 12 MUTATIONS**

The expression of each Jak2 exon 12 mutant in interleukin-3–dependent BaF3/EpoR cells caused
the cells to proliferate in the absence of added exogenous cytokine, with kinetics indistinguishable from those observed for cells with the V617F mutation (Fig. 3A). This proliferation required expression of the erythropoietin receptor; it was not observed in parental BaF3 cells (data not shown). In the absence of stimulation with erythropoietin, all mutants were consistently associated with increased levels of tyrosine-phosphorylated Jak2 and Stat5, as compared with wild-type Jak2 (Fig. 3B). Moreover, the three alleles containing a K539L substitution all generated consistently higher levels of phosphorylated Jak2 than those with the V617F mutation (Fig. 3B). The exon 12 mutants also constitutively activated the Ras–ERK signaling pathway, generating levels of phosphorylated Erk1 and Erk2 that were markedly higher than those obtained with wild-type Jak2 and higher than those obtained with V617F Jak2 (Fig. 3C). In summary, when transduced into BaF3/EpoR cells, all four Jak2 exon 12 mutations caused growth-factor hypersensitivity and activated biochemical pathways associated with erythropoietin signaling.

**Figure 3.** Proliferation and Increased Signaling in the Absence of Exogenous Cytokine from Jak2 Exon 12 Mutations.

BaF3/EpoR cells (10⁶ per cubic millimeter) — transduced with an empty retroviral vector or stably expressing wild-type murine Jak2 or Jak2 with V617F, F537-K539delinsL, H538Q/K539L, K539L, or N542-E543del mutations — were cultured in the absence of interleukin-3 for 4 days (Panel A). On days 2 and 4, we assessed cell numbers and viability in quadruplicate using trypan-blue exclusion. Results reflect four independent experiments; mean (±SD) counts for each cell line at both time points are shown. BaF3/EpoR cells transduced with an empty MSCViresGFP retroviral vector (Panel B), or BaF3/EpoR cells containing wild-type Jak2 or Jak2 with V617F, F537-K539delinsL, H538Q/K539L, N542-E543del, or K539L mutations were depleted of cytokines for 4 hours. Cells were lysed and underwent immunoprecipitation (IP) with antibody specific for Jak2 or Stat5; Western blot (WB) was then performed with antibodies against phosphotyrosine (4G10), total Jak2, phosphotyrosine-694 Stat5, or total Stat5 (Panel B). BaF3/EpoR cells expressing the Jak2 alleles were analyzed by Western blot with antibodies specific for phosphospecific or total extracellular regulated kinase 1 (Erk1) and 2 (Erk2) (Panel C). BaF3/EpoR cells stimulated with 10 U per milliliter of erythropoietin for 10 minutes were used as positive controls in Panels B and C. Plus signs indicate presence and minus signs absence of exogenous Jak2 or erythropoietin.

**RETROVIRAL TRANSFER OF JAK2 MUTATIONS INTO MICE**

To assess the effects of exon 12 mutations in vivo, murine bone marrow cells were transduced with retroviral vectors encoding wild-type, V617F, or K539L Jak2 and then were transplanted into lethally irradiated BALB/c mice, which are especially susceptible to the development of myeloid disorders after transfer of the V617F mutant.⁸ Five weeks after transplantation, animals that received V617F-transduced bone marrow cells had erythrocytosis and leukocytosis (Fig. 4A), results that are consistent with previous observations,⁸
as well as a modest thrombocytosis. Recipients of K539L-transduced cells also had an elevated hematocrit, reticulocytosis, and leukocytosis and a modest thrombocytosis (Fig. 4). Consistent with the human phenotypes associated with exon 12 and V617F mutations, the mean white-cell and platelet counts were lower in recipients of K539L-transduced cells than in recipients of V617F-transduced cells (P=0.005 and P=0.07, respectively). Fluorescence-activated cell-sorting analysis of bone marrow cells from these mice showed that, as compared with wild-type Jak2, K539L-transduced cells resulted in expansion of the erythroid and granulocytic lineages but not those of T lymphocytes, B lymphocytes, or megakaryocytes (data not shown).

**Discussion**

We have identified a distinctive myeloproliferative syndrome, associated with gain-of-function JAK2 exon 12 mutations, that includes patients who are currently given a diagnosis of polycythemia vera or idiopathic erythrocytosis. Patients with JAK2 exon 12 mutations present with erythrocytosis, low serum erythropoietin levels, and a distinctive histologic appearance of the bone marrow. As in other myeloproliferative diseases, erythropoietin-independent erythroid progenitors can be cultured from peripheral-blood cells, and cytogenetic abnormalities, splenomegaly, or transformation to myelofibrosis has been observed in some patients. Unlike erythroid colonies in patients with V617F-positive polycythemia vera, those in patients with exon 12 mutations are not homozygous for the JAK2 mutation.

The diagnosis of individual patients with a myeloproliferative disorder can be difficult.31 Different centers use different diagnostic criteria, and several diagnostic tests are not widely used. A patient may therefore be given a diagnosis of polycythemia vera by one clinician and a diagnosis of idiopathic erythrocytosis by another. Our results emphasize the importance of molecular classifi-

![Figure 4. A Myeloproliferative Phenotype, Resulting from Retroviral Expression of K539L Jak2, in a Murine Model of Bone Marrow Transplantation.](image-url)
cation of these diseases. Exon 12 mutations may have previously been missed when peripheral-blood leukocyte DNA was analyzed, since granulocyte involvement in patients with these mutations is often low. For the molecular diagnosis of this syndrome, it is therefore important to sequence DNA from bone marrow cells or, preferably, from individual clonogenic hematopoietic colonies.

It is not clear how mutations that affect residues 537 through 543 result in unregulated JAK2 activity. To date, only the structure of the JAK2 kinase domain has been elucidated, and for this reason the details of interdomain interactions in JAK2 are unknown. However, homology-based molecular modeling suggests that residues 537 through 543 lie within a region linking the predicted SRC homology 2 (SH2) and JH2 domains of JAK2.

These residues are near the predicted loop carrying V617 in a theoretical model of the full-length JAK2 protein (Fig. 3 in the Supplementary Appendix). Verification of this model awaits detailed structural and biochemical analysis.

Our results also shed light on the various clinical phenotypes associated with exon 12 and V617F mutations. Compared with the V617F mutation, exon 12 mutations result in stronger ligand-independent signaling through JAK2; exon 12 mutations generate higher levels of JAK2 and ERK1 and ERK2 phosphorylation than does the V617F mutation. Moreover, the absence of exon 12 mutations in patients with essential thrombocytopenia accords with the proposal that low levels of JAK2 signaling favor thrombocytosis, whereas more-active signaling favors erythrocytosis.

Supported by grants from the U.K. Leukaemia Research Fund and the Wellcome Trust (to Dr. Green), the Leukemia and Lymphoma Society, the Doris Duke Charitable Foundation, and the Howard Hughes Medical Institute (to Dr. Gilliland), Amgen (to Dr. Lodish), the National Cancer Institute (KO1 CA115679, to Dr. Tong), the National Institutes of Health (P01 HL32262, to Dr. Lodish, and DK50654 and CA66996, to Dr. Gilliland), and the American Society of Hematology and the Doris Duke Charitable Foundation (to Dr. Levine).

No potential conflict of interest relevant to this article was reported.

We thank Romano Kroemer for the coordinates of the JAK2 model; Melanie Pery, Betty Cheung, Anthony Benc, and the staff of the Addenbrooke’s Haematological Disorders Sample Bank for the processing of clinical samples; Sara Zarnegar for technical assistance; Brian Huntly for comments on the manuscript; Yana Pikman for assistance with transplant experiments; and Martha Wadleigh for providing clinical details.

REFERENCES

New JAK2 Mutations and Erythrocytosis


Copyright © 2007 Massachusetts Medical Society.

CLINICAL TRIAL REGISTRATION

The Journal requires investigators to register their clinical trials in a public trials registry. The members of the International Committee of Medical Journal Editors (ICMJE) will consider most clinical trials for publication only if they have been registered (see N Engl J Med 2004;351:1250-1). Current information on requirements and appropriate registries is available at www.icmje.org/faq.pdf.